Entity family
Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.
This disease is selected. Its supporting articles are shown below.
… with an early switch to SLST in patients with oligoprogressive HCC while maintaining an acceptable safety profile.Methods and anal…
…–45.4]; aHR 0.25 [95% CI 0.13–0.51]; p<0.001), particularly for hepatocellular carcinoma (aHR 0.13 [95% CI 0.05–0.36]). PWH with non–virus-related NADCs…
…r, robust evidence supporting this combination in patients with hepatocellular carcinoma (HCC) is lacking. This randomised controlled study aims to comp…
…LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of pat…
…vation of metabolic reprogramming promotes tumor progression in hepatocellular carcinoma. Cell Metab. 2023;35:1183–1199.e6.Guo J, Liu Z, Zhang X, et al.…
… with worse overall survival across multiple cancers, including hepatocellular carcinoma (HCC). Clinical samples showed CD68+ tumor regions associate wi…
…rcinoma (54%), head and neck squamous cell carcinoma (37%), and thyroid cancer (52%), but the distribution of mutations differs across these d…
…ckground Early relapse remains a major challenge in early-stage hepatocellular carcinoma (HCC), with only 30% achieving complete pathological responses …
…lunteers. Animal experiments related to CAR-NK cell therapy for hepatocellular carcinoma were approved by the Institutional Animal Care and Use Committe…
…erogeneity; Genetic deletion of CXCR1 overcome NK exhaustion in Hepatocellular Carcinoma; Anti-CXCR1 therapy inhibits tumor growth in combination with P…
….0002). A double-blind, randomized, placebo-controlled trial in COVID-19 patients14 demonstrated that NP-101 led to a faster decline in …
…ed with tremelimumab (D+T) or bevacizumab (D+B) in unresectable hepatocellular carcinoma (HCC).1 2 We analyzed baseline and end-of-treatment (EOT) abdom…